Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 7
2 Pharmaceuticals & Healthcare, Global, Deal Summary 10
2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, February 2017 10
2.2 Pharmaceuticals & Healthcare, Global, Major Deals, February 2017 12
2.2.1 Pfizer Raises USD4.2 Billion in Public Offering of Notes 12
2.2.2 Royalty Pharma Acquires Royalty Stream of Tysabri from Perrigo for USD2.85 Billion 12
2.2.3 Seattle Genetics to Enter into Licensing Agreement with Immunomedics 13
2.2.4 Quintiles IMS Prices Public Offering of 3.25% Notes Due 2025 for USD1.5 Billion 14
2.2.5 Bristol-Myers Squibb Raises USD1.5 Billion in Public Offering of Notes 14
2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, February 2017 15
2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, February 2017 16
3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 17
3.1 Pharmaceuticals & Healthcare, Global, M&A, February 2017 17
3.1.1 Top M&A Deals in February 2017 18
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, September 2016- February 2017 19
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, February 2017 20
3.2.1 Top Equity Offering Deals in February 2017 21
3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, September 2016- February 2017 22
3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, February 2017 23
3.3.1 Top PE/VC Deals in February 2017 24
3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, February 2017 25
3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, February 2017 26
3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, August 2016-February 2017 28
3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, August 2016-February 2017 29
3.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, February 2017 30
3.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, September 2016- February 2017 31
3.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), February 2017 32
3.6.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, February 2017 33
3.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), September 2016- February 2017 34
3.8 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, September 2016- February 2017 36
3.9 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), September 2016- February 2017 37
3.10 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), September 2016- February 2017 38
4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, February 2017 39
4.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, February 2017 39
4.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), February 2017 40
4.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), September 2016- February 2017 41
4.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), September 2016- February 2017 42
4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), September 2016- February 2017 43
4.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), September 2016- February 2017 45
4.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, February 2017 46
4.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, February 2017 46
4.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, February 2017 47
5 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 48
5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, February 2017 48
5.1.1 Oncology - Deals of the Month 49
5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, February 2017 51
5.2.1 Central Nervous System - Deals of the Month 52
5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, February 2017 54
5.3.1 Infectious Diseases - Deals of the Month 55
5.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, February 2017 57
5.4.1 Cardiovascular - Deal of the Month 58
5.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, February 2017 59
5.5.1 Immunology - Deals of the Month 60
5.6 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, February 2017 62
5.6.1 Gastrointestinal - Deal of the Month 63
5.7 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, February 2017 65
5.7.1 Metabolic Disorders - Deal of the Month 66
6 Deal Summary by Geography 68
6.1 Pharmaceuticals & Healthcare, North America Deals, February 2017 68
6.1.1 North America - Deals of the Month 69
6.2 Pharmaceuticals & Healthcare, Europe, Deals, February 2017 71
6.2.1 Europe - Deals of the Month 72
6.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, February 2017 74
6.3.1 Asia-Pacific - Deals of the Month 75
6.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, February 2017 77
6.4.1 Rest of the World - Deals of the Month 78
7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 79
7.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, September 2016- February 2017 79
7.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, September 2016- February 2017 80
8 Further Information 81
8.1 Methodology 81
8.2 About GlobalData 82
8.3 Contact Us 82
8.4 Disclosure information 82
8.5 Disclaimer 83
List of Tables
Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), September 2016- February 2017 11
Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, February 2017 12
Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), February 2017 16
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), September 2016- February 2017 18
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, February 2017 18
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, September 2016- February 2017 19
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), September 2016- February 2017 21
Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, February 2017 21
Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), September 2016- February 2017 22
Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), September 2016- February 2017 24
Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, February 2017 24
Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, September 2016- February 2017 25
Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number OfDeals and Deal Values (%),February 2017 27
Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), September 2016- February 2017 28
Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, September 2016- February 2017 29
Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), September 2016- February 2017 30
Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), September 2016- February 2017 31
Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), September 2016- February 2017 32
Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), February 2017 33
Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), September 2016- February 2017 35
Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, September 2016- February 2017 37
Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), September 2016- February 2017 38
Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), September 2016- February 2017 39
Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), September 2016- February 2017 40
Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), September 2016- February 2017 41
Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), February 2017 42
Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, September 2016- February 2017 44
Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), February 2017 45
Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, February 2017 46
Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, February 2017 46
Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, February 2017 47
Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), September 2016- February 2017 49
Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), September 2016- February 2017 52
Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), September 2016- February 2017 55
Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), September 2016- February 2017 58
Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), September 2016- February 2017 60
Table 37: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), September 2016- February 2017 63
Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), September 2016- February 2017 66
Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), September 2016- February 2017 69
Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), September 2016- February 2017 72
Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), September 2016- February 2017 75
Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), September 2016- February 2017 77
Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), September 2016- February 2017 79
Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), September 2016- February 2017 80
List of Figures
Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), September 2016- February 2017 10
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), February 2017 15
Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), February 2017 16
Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), September 2016- February 2017 17
Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, September 2016- February 2017 19
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), September 2016- February 2017 20
Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), September 2016- February 2017 22
Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), September 2016- February 2017 23
Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, September 2016- February 2017 25
Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), February 2017 26
Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%),February 2017 27
Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), September 2016- February 2017 28
Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), September 2016- February 2017 30
Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), September 2016- February 2017 31
Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), September 2016- February 2017 32
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), September 2016- February 2017 34
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, September 2016- February 2017 36
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, September 2016- February 2017 37
Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), September 2016- February 2017 38
Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), September 2016- February 2017 39
Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), September 2016- February 2017 40
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), September 2016- February 2017 41
Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), September 2016- February 2017 42
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals,September 2016- February 2017 43
Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m),September 2016- February 2017 44
Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), February 2017 45
Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), September 2016- February 2017 48
Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), September 2016- February 2017 51
Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), September 2016- February 2017 54
Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), September 2016- February 2017 57
Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), September 2016- February 2017 59
Figure 32: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), September 2016- February 2017 62
Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), September 2016- February 2017 65
Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), September 2016- February 2017 68
Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), September 2016- February 2017 71
Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), September 2016- February 2017 74
Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), September 2016- February 2017 77
Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), September 2016- February 2017 79
Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), September 2016- February 2017 80
